| Jacob Michael Oaklyn, LCSW | |
|
48 N 1100 E Ste B, American Fork, UT 84003-2910 | |
| (801) 369-8989 | |
| (801) 704-9741 |
| Full Name | Jacob Michael Oaklyn |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 48 N 1100 E Ste B, American Fork, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275139339 | NPI | - | NPPES |
| Entity Name | Valley Mental Health Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275599797 PECOS PAC ID: 0042121196 Enrollment ID: O20031111000937 |
News Archive
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area with a long experience in respiratory disease therapies, woman care and primary care, announce that the New Drug Application (NDA) for safinamide was submitted today to the US Food and Drug Administration (FDA).
A new study, conducted by a team of researchers from the University of California, San Diego, has identified how the environment surrounding a tumor can stimulate metastatic behavior in the individual cancer cells. Researchers found that the tumor cells activate a particular set of genes and begin to form blood vessel-like structures when they are confined in a densely packed environment.
One specific protein may be a master regulator for changing how cancer cells consume nutrients from their environments, preventing cell death and increasing the likelihood cancer could spread, a study from the University of Notre Dame has shown.
Researchers at St. Michael's Hospital in Toronto are part of an international team of researchers recently awarded a multi-million dollar grant for their work in cardiovascular disease among Indigenous people in Canada, Australia and New Zealand. The Canadian team will receive $742,000 in funding for its part of the project from the Canadian Institutes of Health Research and International Collaborative Indigenous Health Research Partnerships.
In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors.
› Verified 5 days ago
| Entity Name | Cedar Psychiatry Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265092282 PECOS PAC ID: 2163750688 Enrollment ID: O20190822000230 |
News Archive
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area with a long experience in respiratory disease therapies, woman care and primary care, announce that the New Drug Application (NDA) for safinamide was submitted today to the US Food and Drug Administration (FDA).
A new study, conducted by a team of researchers from the University of California, San Diego, has identified how the environment surrounding a tumor can stimulate metastatic behavior in the individual cancer cells. Researchers found that the tumor cells activate a particular set of genes and begin to form blood vessel-like structures when they are confined in a densely packed environment.
One specific protein may be a master regulator for changing how cancer cells consume nutrients from their environments, preventing cell death and increasing the likelihood cancer could spread, a study from the University of Notre Dame has shown.
Researchers at St. Michael's Hospital in Toronto are part of an international team of researchers recently awarded a multi-million dollar grant for their work in cardiovascular disease among Indigenous people in Canada, Australia and New Zealand. The Canadian team will receive $742,000 in funding for its part of the project from the Canadian Institutes of Health Research and International Collaborative Indigenous Health Research Partnerships.
In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jacob Michael Oaklyn, LCSW 672 W 400 S Ste 201, Springville, UT 84663-3170 Ph: (801) 369-8989 | Jacob Michael Oaklyn, LCSW 48 N 1100 E Ste B, American Fork, UT 84003-2910 Ph: (801) 369-8989 |
News Archive
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area with a long experience in respiratory disease therapies, woman care and primary care, announce that the New Drug Application (NDA) for safinamide was submitted today to the US Food and Drug Administration (FDA).
A new study, conducted by a team of researchers from the University of California, San Diego, has identified how the environment surrounding a tumor can stimulate metastatic behavior in the individual cancer cells. Researchers found that the tumor cells activate a particular set of genes and begin to form blood vessel-like structures when they are confined in a densely packed environment.
One specific protein may be a master regulator for changing how cancer cells consume nutrients from their environments, preventing cell death and increasing the likelihood cancer could spread, a study from the University of Notre Dame has shown.
Researchers at St. Michael's Hospital in Toronto are part of an international team of researchers recently awarded a multi-million dollar grant for their work in cardiovascular disease among Indigenous people in Canada, Australia and New Zealand. The Canadian team will receive $742,000 in funding for its part of the project from the Canadian Institutes of Health Research and International Collaborative Indigenous Health Research Partnerships.
In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors.
› Verified 5 days ago
Dalton Boley, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 150 S 400 E, American Fork, UT 84003 Phone: 801-984-1717 | |
Eva I Calvillo Chavira, CSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 796 E Pacific Dr Ste A, American Fork, UT 84003 Phone: 801-642-2491 Fax: 801-216-4566 | |
Martha Hardy, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 154 S 980 E, American Fork, UT 84003 Phone: 801-691-2414 Fax: 801-753-0397 | |
Connie Lynn Winn, Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 578 E 300 S # 101, American Fork, UT 84003 Phone: 801-763-5010 | |
Melissa Jane Williams, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 433 S 500 E, American Fork, UT 84003 Phone: 801-216-8000 | |
Molly Anne Capcha, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 538 S 500 E, American Fork, UT 84003 Phone: 801-642-2515 | |
Mr. Raymond H Burgoyne, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 433 S 500 E, American Fork, UT 84003 Phone: 801-216-8000 Fax: 801-216-8001 |